Godavari Drugs Ltd

Godavari Drugs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 10 February 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 10 February 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Godavari Drugs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 10 February 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 30 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Godavari Drugs Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 10 February 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Godavari Drugs Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 10 February 2025, reflecting a reassessment of the company’s outlook. However, the analysis and financial metrics presented here are based on the stock’s current position as of 07 January 2026, providing investors with the latest insights into its performance and prospects.

Godavari Drugs Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 10 February 2025, reflecting a reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below represent the company’s current position as of 25 December 2025, providing investors with the latest insights into its performance and prospects.

Godavari Drugs has reached a new 52-week low of Rs.69.7, marking a significant decline in its stock price amid a challenging market environment and subdued financial performance over the past year.

Godavari Drugs has reached a new 52-week low of Rs.70.31 today, marking a significant decline in its stock price amid ongoing downward momentum. The pharmaceutical company’s shares have been under pressure, reflecting a series of financial and market challenges over the past year.

Godavari Drugs has reached a new 52-week low of Rs.70.31, marking a significant decline in its stock price amid ongoing downward momentum. The pharmaceutical and biotechnology company’s shares have been under pressure, reflecting a series of financial and market challenges over the past year.

Godavari Drugs has reached a new 52-week low of Rs.70.31, marking a significant decline in its stock price amid ongoing downward momentum. The pharmaceutical company’s shares have been under pressure, reflecting a series of financial and market challenges over the past year.

Godavari Drugs has experienced a revision in its market evaluation reflecting ongoing challenges in its financial and technical outlook. The pharmaceutical microcap’s recent assessment highlights a cautious stance driven by subdued sales growth, persistent negative earnings, and bearish trading patterns.

Godavari Drugs has reached a new 52-week low of Rs.72.11, marking a significant decline in its stock price amid a challenging market environment and subdued financial performance over the past year.

Godavari Drugs has reached a new 52-week low of Rs.73.2, marking a significant decline in its stock price amid a sustained downward trend over recent sessions. The pharmaceutical company’s shares have been under pressure, reflecting a series of financial and market factors that have influenced its performance.

Godavari Drugs has reached a new 52-week low of Rs.74, marking a significant milestone in its ongoing price decline. The stock’s performance over the past year reflects a challenging period for the company within the Pharmaceuticals & Biotechnology sector.

Godavari Drugs has reached a new 52-week low of Rs.74, marking a significant milestone in its ongoing price decline. This development reflects a continuation of the stock’s subdued performance over the past year, contrasting with broader market gains.

Godavari Drugs has reached a new 52-week low of Rs.74, marking a significant milestone in its recent price movement. This decline reflects ongoing pressures on the stock within the Pharmaceuticals & Biotechnology sector, as it trades below all key moving averages amid broader market gains.

Godavari Drugs has reached a new 52-week low of Rs.75.2, marking a significant decline in its stock price amid ongoing downward momentum. The pharmaceutical company’s shares have been under pressure, reflecting a series of financial and market challenges over the past year.

Godavari Drugs has reached a new 52-week low, with its share price touching Rs.75.45 today. This marks a significant decline for the pharmaceutical company amid broader market fluctuations and sectoral pressures.